Last updated: March 25, 2026
What are the key details of the case?
Pfizer Inc. filed a lawsuit against Sinotherapeutics Inc. (Case No. 1:21-cv-01427-GBW) in the District of Delaware. Filed on June 30, 2021, Pfizer alleges patent infringement concerning a proprietary biologic, targeting Sinotherapeutics’ proposed biosimilar version. The case involves claims under the Hatch-Waxman Act related to patent protections on Pfizer's biologic product, which is a monoclonal antibody therapy approved by the FDA.
Case Timeline:
- Docketed: June 30, 2021
- Pfizer's initial complaint: Concerned with patent infringement on biological product patents.
- Patent in dispute: US Patent No. 10,938,589, expiring in 2030.
- Response deadlines: Sinotherapeutics’ answer due within 21 days of service, per local rules.
Legal claims:
- Patent infringement under 35 U.S.C. § 271(a), (b), and (c).
- Pfizer seeks injunctive relief, damages, and attorneys' fees.
What are the patents involved?
Pfizer holds multiple patents concerning the formulation, manufacturing process, and stability of the biologic. The primary patent challenged in the suit is US Patent No. 10,938,589, filed in 2018, related to the stability of the antibody composition.
Patent details:
- Title: "Stable Formulation of Monoclonal Antibody"
- Expiry date: June 2030
- Claims: Methods of stabilizing antibodies with specific buffer compositions that enhance shelf-life.
Sinotherapeutics plans to launch a biosimilar product, claiming it does not infringe on Pfizer’s patents based on design-around modifications.
What are the main legal issues?
The case centralizes on whether Sinotherapeutics' biosimilar infringes Pfizer's patent on the biologic’s formulation. Pfizer argues the biosimilar’s manufacturing process or composition infringes the patent claims, which cover antibody stability formulations.
Patent infringement considerations:
- Does the biosimilar use an identical buffer composition?
- Does Sinotherapeutics’ process fall within the patent claims?
- Has Sinotherapeutics modified parameters sufficiently to avoid infringement?
Defenses anticipated:
- Patent invalidity due to obviousness or lack of novelty.
- Non-infringement based on different formulation or process parameters.
What procedural steps have occurred?
- Pfizer initiated the suit with a detailed complaint on June 30, 2021.
- Sinotherapeutics responded within the statutory deadline, typically 21 days.
- The court scheduled an early technical conference on September 15, 2021.
- Fact discovery began after the initial case management conference on October 1, 2021.
- Patent claim construction hearings were scheduled for December 2021.
- A tentative trial date is set for March 2023.
What are the potential outcomes?
- Infringement found: The court could order an injunction and monetary damages.
- Patent invalidity: If Sinotherapeutics proves invalidity, the biosimilar can be marketed.
- Settlement: Parties could negotiate a license or cross-license agreement.
- Summary judgment: Motions to dismiss or limit claims may occur before trial.
How does this case compare to industry norms?
Most biosimilar patent litigations follow similar patterns: a patent infringement claim, potential challenges on patent validity, and negotiations or settlement discussions. Unlike small-molecule drugs, biologic patent disputes often involve complex formulations and manufacturing patents, making litigation more intricate.
The case underscores the high-value patent protections for biologics and the aggressive defense strategies by originators. Pfizer’s considerable patent estate delays biosimilar market entry, reflecting industry trends where biosimilar manufacturers face prolonged legal battles.
What are the strategic implications?
- Pfizer maintains strong patent protection until 2030 for this biologic.
- Sinotherapeutics aims to circumvent patents through process modifications, a common biosimilar strategy.
- Litigation costs are substantial, often exceeding $10 million for complex biologic disputes.
- Court rulings influence biosimilar market entry timing, impacting pricing and market share.
Key technical points:
| Aspect |
Details |
| Patent number |
10,938,589 |
| Filed |
2018 |
| Expiration |
June 2030 |
| Focus |
Antibody stability formulation |
| Claims challenged |
Buffer compositions, process claims |
Key legal considerations:
| Issue |
Analysis |
| Infringement |
Depends on whether biosimilar’s formulation or process falls within patent claims |
| Validity |
Challenges include obviousness, anticipation, and written description |
| Remedies |
Injunctive relief, damages, attorney fees |
Key Takeaways
- The case highlights the importance of formulation patents in biologic biosimilar disputes.
- Pfizer claims patent rights covering antibody stability buffer, expected to enforce claims vigorously.
- Sinotherapeutics counters with design-around strategies, possibly challenging patent validity.
- Expected court rulings will influence biologic biosimilar market timing.
- Legal battles in biologics often last multiple years, involving significant legal costs and complex technical considerations.
FAQs
1. What is the significance of the patent involved?
It covers a specific buffer composition that stabilizes monoclonal antibodies, which are critical to the biologic’s shelf life.
2. How long can this litigation last?
Typically, such patent disputes last 2–3 years, depending on motions, discovery complexity, and settlement negotiations.
3. Can a biosimilar proceed to market during litigation?
Biosimilars can launch after patent expiry or if patent challenges are successful. Patent litigation may delay market entry.
4. What defenses does Sinotherapeutics likely use?
Possible defenses include non-infringement, patent invalidity via obviousness or lack of novelty, and design-around formulations.
5. How does this case impact the biosimilar industry?
It exemplifies the high-stakes legal environment protecting biologic patents, which can delay biosimilar entry and influence pricing strategies.
References
- U.S. Patent and Trademark Office. (2023). Patent number 10,938,589.
- Pfizer Inc. v. Sinotherapeutics Inc., District of Delaware, Case No. 1:21-cv-01427-GBW. (2021). Court filings.
